Amarin Corporation plc - American Depositary Shares, each repre — Bilan (NASDAQ:AMRN)

Financials

Total de l'actif 966.02 M1.07 B886.18 M831.68 M685.35 M670.77 M Total du passif 338.52 M400.97 M290.85 M279.59 M199.17 M211.49 M Total des capitaux propres 627.5 M667.1 M595.33 M552.1 M486.18 M459.28 M Total du passif et des capitaux propres 966.02 M1.07 B886.18 M831.68 M685.35 M670.77 M Dette totale —————— Dette nette ——————

Amarin Corporation plc - American Depositary Shares, each repre

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza.

AMRN

Financials

Amarin Corporation plc - American Depositary Shares, each repre

Nouvelles

ABBV Seeks FDA Nod for Rinvoq Label Expansion in Alopecia Areata

Amarin Q1 2026 : croissance du chiffre d’affaires malgré la restructuration

Novartis Q1 Earnings & Revenues Miss Estimates, Stock Down

AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues

Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?

AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results

MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study

MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study

MRK's sBLAs for Keytruda Combo in Bladder Cancer Get FDA Priority Tag

BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up

Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up

Amarin présentera les données de sous-groupes de REDUCE-IT lors d’un congrès de cardiologie